{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:00:03Z","timestamp":1790200803799,"version":"4.1.0"},"reference-count":51,"publisher":"Impact Journals, LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,1,20]]},"DOI":"10.18632\/oncotarget.2731","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T08:03:59Z","timestamp":1442304239000},"page":"1128-1142","source":"Crossref","is-referenced-by-count":33,"title":["Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma"],"prefix":"10.18632","volume":"6","author":[{"given":"Iris Chiara","family":"Salaroglio","sequence":"first","affiliation":[{"name":"Department of Oncology, University of Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Campia","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Kopecka","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gazzano","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Orecchia","sequence":"additional","affiliation":[{"name":"S.C. Anatomia Patologica, Azienda Ospedaliera S.S. Antonio e Biagio, Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Ghigo","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Riganti","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2014,12,31]]},"reference":[{"key":"1","first-page":"428","article-title":"Systematic review of trimodality therapy for patients with malignant pleural mesothelioma","volume":"1","author":"Yan","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"2","first-page":"508","article-title":"Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future","volume":"1","author":"Nowak","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"3","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ctrv.2012.12.005","article-title":"Malignant mesothelioma: new insights into a rare disease","volume":"39","author":"Zanui","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/CCO.0000000000000053","article-title":"Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements","volume":"26","author":"Eberhardt","year":"2014","journal-title":"Curr Opin Oncol"},{"key":"5","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/cgt.2013.1","article-title":"Gene therapy for malignant mesothelioma: current prospects and challenges","volume":"20","author":"Hiroshima","year":"2013","journal-title":"Cancer Gene Ther"},{"key":"6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0039.2009.01275.x","article-title":"Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma","volume":"74","author":"Lake","year":"2009","journal-title":"Tissue Antigens"},{"key":"7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.canlet.2012.02.034","article-title":"Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies","volume":"322","author":"Bei","year":"2012","journal-title":"Cancer Lett"},{"key":"8","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jtcvs.2009.11.072","article-title":"Prevalence ofchemotherapeutic drug resistance in primary malignant pleural mesothelioma: result in a cohort of 203 resection specimens","volume":"140","author":"Sugarbaker","year":"2010","journal-title":"J Thorac Cardiovasc Surg"},{"key":"9","doi-asserted-by":"crossref","first-page":"13021","DOI":"10.1074\/jbc.M709698200","article-title":"Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids","volume":"283","author":"Broaddus","year":"2008","journal-title":"J Biol Chem"},{"key":"10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2012.07.005","article-title":"Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy","volume":"78","author":"Felley-Bosco","year":"2012","journal-title":"Lung Cancer"},{"key":"11","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/onc.2009.478","article-title":"Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells","volume":"29","author":"Takahashi","year":"2010","journal-title":"Oncogene"},{"key":"12","doi-asserted-by":"crossref","first-page":"e1167","DOI":"10.1038\/cddis.2014.136","article-title":"Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation","volume":"5","author":"Pass","year":"2014","journal-title":"Cell Death Dis"},{"key":"13","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/carcin\/bgq026","article-title":"Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy","volume":"31","author":"Poulain","year":"2010","journal-title":"Carcinogenesis"},{"key":"14","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1038\/onc.2011.485","article-title":"SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells","volume":"31","author":"Strano","year":"2012","journal-title":"Oncogene"},{"key":"15","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1023\/A:1012292230480","article-title":"The expression of P-glycoprotein and multidrug resistance proteins 1 and 2 (MRP1 and MRP2) in human malignant mesothelioma","volume":"12","author":"Kinnula","year":"2001","journal-title":"Ann Oncol"},{"key":"16","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1183\/09031936.00090407","article-title":"Asbestos induces doxorubicin resistance in MM98 mesothelioma cells via HIF-1alpha","volume":"32","author":"Bosia","year":"2008","journal-title":"Eur Respir J"},{"key":"17","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1038\/onc.2010.643","article-title":"Onconase mediated NFK\u03b2 downregulation in malignant pleural mesothelioma","volume":"30","author":"Pass","year":"2011","journal-title":"Oncogene"},{"key":"18","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1017\/S1462399411001888","article-title":"Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain","volume":"13","author":"Elmquist","year":"2011","journal-title":"Expert Rev Mol Med"},{"key":"19","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1183\/09031936.06.00135305","article-title":"Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses","volume":"27","author":"Lambrecht","year":"2006","journal-title":"Eur Respir J"},{"key":"20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/478192a","article-title":"Cancer: Why tumors eat tryptophan","volume":"478","author":"Prendergast","year":"2011","journal-title":"Nature"},{"key":"21","doi-asserted-by":"crossref","first-page":"e60975","DOI":"10.1371\/journal.pone.0060975","article-title":"Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells","volume":"8","author":"Massaia","year":"2013","journal-title":"PLoS One"},{"key":"22","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1158\/1078-0432.CCR-05-2766","article-title":"Bisphosphonates inhibit the growth of mesothelioma cellsand","volume":"12","author":"Selander","year":"2006","journal-title":"Clin Cancer Res"},{"key":"23","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/JTO.0b013e31824c7d43","article-title":"Zoledronic acid produces antitumor effects on mesothelioma through apoptosis and S-phase arrest in p53-independent and Ras prenylation-independent manners","volume":"7","author":"Tagawa","year":"2012","journal-title":"J Thorac Oncol"},{"key":"24","doi-asserted-by":"crossref","first-page":"e60297","DOI":"10.1371\/journal.pone.0060297","article-title":"Zoledronic acid produces combinatory anti-tumor effects with cisplatin on mesothelioma by increasing p53 expression levels","volume":"8","author":"Tagawa","year":"2013","journal-title":"PLoS One"},{"key":"25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/sj.bjc.6605814","article-title":"Zoledronic acid impairs myeloid differentiation to tumor-associated macrophages in mesothelioma","volume":"103","author":"Aerts","year":"2010","journal-title":"Br J Cancer"},{"key":"26","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.2174\/138161210793563545","article-title":"Nitrogen-containing bisphosphonates and cancer immunotherapy","volume":"16","author":"Massaia","year":"2010","journal-title":"Curr Pharm Des"},{"key":"27","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1038\/sj.onc.1210939","article-title":"A keyantitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase","volume":"27","author":"Muller","year":"2008","journal-title":"Oncogene"},{"key":"28","first-page":"269","article-title":"Indoleamine 2, 3-dioxygenase and regulatory function: tryptophan starvation and beyond","volume":"677","author":"Grohmann","year":"2011","journal-title":"Methods Mol Biol"},{"key":"29","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.4049\/jimmunol.0804388","article-title":"Cutting edge: Negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3","volume":"182","author":"Reddy","year":"2009","journal-title":"J Immunol"},{"key":"30","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cytogfr.2008.08.004","article-title":"IFNgamma signaling-does it mean JAK-STAT?","volume":"19","author":"Clarke","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"key":"31","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0092-8674(95)90311-9","article-title":"Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation","volume":"82","author":"Darnell","year":"1995","journal-title":"Cell"},{"key":"32","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1182\/blood-2009-10-230060","article-title":"STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells","volume":"115","author":"Estrov","year":"2010","journal-title":"Blood"},{"key":"33","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1242\/jcs.00963","article-title":"The JAK\/STAT signaling pathway","volume":"117","author":"Harrison","year":"2004","journal-title":"J Cell Sci"},{"key":"34","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.cyto.2006.12.003","article-title":"STAT1 and STAT3 phosphorylation by porins are independent of JAKs but are dependent on MAPK pathway and plays a role in U937 cells production of interleukin-6","volume":"36","author":"Galdiero","year":"2006","journal-title":"Cytokine"},{"key":"35","doi-asserted-by":"crossref","first-page":"12032","DOI":"10.1073\/pnas.211026798","article-title":"SV40 replication in human mesothelial cells induces HGF\/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma","volume":"98","author":"Gaudino","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"36","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/ijc.25763","article-title":"ERK2 is essential for the growth of human epithelioid malignant mesotheliomas","volume":"129","author":"Mossman","year":"2011","journal-title":"Int J Cancer"},{"key":"37","doi-asserted-by":"crossref","first-page":"e314","DOI":"10.1186\/1476-4598-9-314","article-title":"Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin","volume":"9","author":"Mossman","year":"2010","journal-title":"Mol Cancer"},{"key":"38","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/02841860600996447","article-title":"Theanti-tumor activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer","volume":"46","author":"Leonard","year":"2007","journal-title":"Acta Oncol"},{"key":"39","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12307-012-0100-4","article-title":"The Role of Regulatory T Cells in Mesothelioma","volume":"5","author":"Beilharz","year":"2012","journal-title":"Cancer Microenviron"},{"key":"40","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1136\/thx.2007.085241","article-title":"EGFR, and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors","volume":"63","author":"Popper","year":"2008","journal-title":"Thorax"},{"key":"41","doi-asserted-by":"crossref","first-page":"6508","DOI":"10.1128\/MCB.17.11.6508","article-title":"STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation","volume":"17","author":"Blenis","year":"1997","journal-title":"Mol Cell Biol"},{"key":"42","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4196\/kjpp.2009.13.3.161","article-title":"Extracellular Signal-regulated Kinase Activation Is Required for Serine 727 Phosphorylation of STAT3 in Schwann Cellsand","volume":"13","author":"Park","year":"2009","journal-title":"Korean J Physiol Pharmacol"},{"key":"43","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ijc.27611","article-title":"SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma","volume":"132","author":"Naka","year":"2013","journal-title":"Int J Cancer"},{"key":"44","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1186\/1476-4598-12-137","article-title":"Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition","volume":"12","author":"Riganti","year":"2013","journal-title":"Mol Cancer"},{"key":"45","first-page":"207","article-title":"Generalized equations for the analysis of inhibitors of Michaelis-Menten and higher order kinetic systems with two or more mutually exclusive and non-exclusive inhibitors","volume":"115","author":"Talalay","year":"1981","journal-title":"Eur J Biochem"},{"key":"46","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1161\/01.RES.87.7.526","article-title":"Targeting Rho in cardiovascular disease","volume":"87","author":"Liao","year":"2000","journal-title":"Circ Res"},{"key":"47","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1158\/1535-7163.MCT-06-0343","article-title":"Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications","volume":"6","author":"Goldman","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"48","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1186\/1471-2407-12-4","article-title":"HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast","volume":"12","author":"Sapino","year":"2012","journal-title":"BMC Cancer"},{"key":"49","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.7314\/APJCP.2013.14.9.5507","article-title":"DNA repair capacity in peripheral blood lymphocytes predicts efficacy of platinum-based chemotherapy in patients with gastric cancer","volume":"14","author":"Gu","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"50","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/1535-7163.MCT-13-0862","article-title":"BRCA2 and RAD51 Promote Double-Strand Break Formation and Cell Death in Response to Gemcitabine","volume":"13","author":"Petermann","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"51","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1158\/0008-5472.CAN-06-2925","article-title":"Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses","volume":"67","author":"Munn","year":"2007","journal-title":"Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.2731","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T15:03:27Z","timestamp":1594825407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.2731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,31]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,1,20]]}},"alternative-id":["2731","25544757"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.2731","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,31]]}}}